Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 29 of the 52 sources its claims cite were checked for support.

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Open access

Published version of a preprint

Abstract

Recent progress in targeting KRAS G12C has provided both insight and inspiration for targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and anti-tumor efficacy of MRTX1133, a potent, selective and non-covalent KRAS G12D inhibitor. MRTX1133 demonstrated a high-affinity interaction with GDP-loaded KRAS G12D with K D and IC 50 values of ~0.2 pM and <2 nM, respectively, and ~700-fold selectivity for binding to KRAS G12D as compared to KRAS WT. MRTX1133 also demonstrated potent inhibition of activated KRAS G12D based on biochemical and co-crystal structural analyses. MRTX1133 inhibited ERK1/2 phosphorylation and cell viability in KRAS G12D-mutant cell lines, with median IC 50 values of ~5 nM, and demonstrated >1,000-fold selectivity compared to KRAS WT cell lines. MRTX1133 exhibited dose-dependent inhibition of KRAS-mediated signal transduction and marked tumor regression (≥30%) in a subset of KRAS G12D-mutant cell-line-derived and patient-derived xenograft models, including eight of 11 (73%) pancreatic ductal adenocarcinoma (PDAC) models. Pharmacological and CRISPR-based screens demonstrated that co-targeting KRAS G12D with putative feedback or bypass pathways, including EGFR or PI3Kα, led to enhanced anti-tumor activity. Together, these data indicate the feasibility of selectively targeting KRAS mutants with non-covalent, high-affinity small molecules and illustrate the therapeutic susceptibility and broad dependence of KRAS G12D mutation-positive tumors on mutant KRAS for tumor cell growth and survival.

Overview

CoChat Summary

TL;DR

MRTX1133 is a potent, selective, non-covalent KRASG12D inhibitor identified by structure-based drug design that binds both inactive and active KRASG12D and inhibits KRAS-dependent signaling. In preclinical models it produced marked tumor regression in KRASG12D-mutant xenografts, especially pancreatic ductal adenocarcinoma, and showed enhanced activity in rational combinations.

Key findings

  • MRTX1133 bound GDP-bound KRASG12D with a SPR KD of ~0.2 pM versus 140 nM for KRAS WT (~700-fold selectivity); HTRF IC50 was <2 nM for inactive KRASG12D and 9 nM for active KRASG12D effector interaction.
  • In KRASG12D-mutant cell lines, MRTX1133 inhibited pERK in 24/25 lines with IC50 values of 0.6–13.7 nM (median 6.1 nM), versus median >3,000 nM in nonKRASG12D lines; viability IC50 medians were 5.3 nM in 3D and 26 nM in 2D assays.
  • In vivo, MRTX1133 at 30 mg/kg BID caused 85% regression in HPAC xenografts, 16% regression at 10 mg/kg BID, and 81% tumor growth inhibition at 3 mg/kg BID; in Panc 04.03, 10 and 30 mg/kg BID produced 60% and 74% regression, respectively.
  • Across 25 KRASG12D-mutant models, 11/25 had ≥30% tumor regression, including 8/11 (73%) PDAC and 2/8 (25%) CRC models; no significant efficacy was seen in four nonKRASG12D-mutant models. Cetuximab plus MRTX1133 improved anti-tumor efficacy in all 7 models tested, and BYL-719 combinations increased activity in CRC and pancreatic models.

Methods

  • Structure-based drug design, SPR binding assays, HTRF competition/effector interaction assays, X-ray crystallography, and cellular signaling/viability assays across 25 KRASG12D-mutant and 7 nonKRASG12D-mutant cancer cell lines.
  • In vivo studies used immunocompromised mice bearing subcutaneous or orthotopic cell line-derived xenografts and patient-derived xenografts; MRTX1133 was administered intraperitoneally at 3, 10, or 30 mg/kg BID, with tumor volume, immunohistochemistry, active RAS ELISA, RNAseq, CRISPR/Cas9 screens, and combination screens.
  • Statistical comparisons used ANOVA or two-tailed Student’s t-test with p<0.05 considered significant; group sizes were typically n=3–6 mice per group.

Limitations

  • The paper states that the level of oncogene addiction to KRASG12D in cancers harboring this mutation is not fully understood; that lower PTEN and CDKN2A RNA expression trends did not reach statistical significance; and that KEAP1 findings were from a preliminary analysis. It also notes that consequences of targeting KRAS WT in adult mammals are unknown.
  • Evident from the text: all efficacy and safety data are preclinical (cell lines and mouse xenograft/orthotopic models), with no human clinical outcomes; MRTX1133 was given intraperitoneally in mice, not by a clinically validated route; and feedback reactivation of ERK/S6 was observed, which may limit response durability.
  • The provided text is a preprint that explicitly states it has not undergone peer review and should not be considered conclusive.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02007-7

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1
Figure 1 From the PDF
Image 2
From the PDF
Image 3
From the PDF
Figure 4
Figure 4 From the PDF
Figure 5
Figure 5 From the PDF
Image 6
From the PDF

Verification

Claims the paper makes

13 Valid · 5 Not valid · 12 Not checked · 106 Own results and interpretations

74 more claims · 2 with their cited sources checked

Create a free account to see all 136 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 50

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 49 references

Cited by

See all 553

Metadata

Authors
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., Trinh, D., Hoffman, N., Wang, X., David Lawson, J., Gunn, R. J., Smith, C. R., Thomas, N. C., Martinson, M., Bergstrom, A., Sullivan, F., Bouhana, K., Winski, S., He, L., Fernandez-Banet, J., Pavlicek, A., Haling, J. R., Rahbaek, L., Marx, M. A., Olson, P., & Christensen, J. G.
Affiliations
  • Mirati Therapeutics (United States) (US)
  • Array BioPharma (United States) (US)
Corresponding author
Christensen, James G.
Venue
Nature Medicine
Published
2022-10
Volume
28
Issue
10
Pages
2171-2182
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4304084008
Cited by
553
References
49
Citations by year
2026: 159 · 2025: 159 · 2024: 138 · 2023: 90 · 2022: 7
FWCI
28.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • Research Square (submittedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Energy (DE‐ AC02‐06CH11357, Contract No. DE-AC02-06CH11357., AC02‐06CH11357, S10OD021527, P30 GM124165, 06CH11357, No. DE-AC02-06CH11357, DE-AC02-)
  • National Institutes of Health (S10OD021527, DE-AC02–06CH11357)
  • Office of Science (P30 GM124165, Contract No. DE-AC02-06CH11357, AC02‐06CH11357, DE-AC02, No. DE-AC02-06CH11357., 06CH11357, DE-AC02-06CH11357)
  • National Institute of General Medical Sciences (DE-AC02-06CH11357, P30GM124165)
  • Office of Research Infrastructure Programs, National Institutes of Health (S10OD021527)
  • Argonne National Laboratory (DE- AC02-06-CH11357, DE-AC02, AC02–06CH11357, No. DE-AC02-06CH11357, 06CH11357, Contract No. DE-AC02-06CH11357., P30 GM124165)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12D, MRTX1133, structure-based drug design, ERK1/2 phosphorylation, EGFR, PI3Kα, pancreatic ductal adenocarcinoma, patient-derived xenografts, antitumor efficacy, co-targeting
MeSH terms
Humans, Mutation, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Cell Line, Tumor, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. https://app.cochat.ai/papers/10.1038/s41591-022-02007-7
The paper
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., Trinh, D., Hoffman, N., Wang, X., David Lawson, J., Gunn, R. J., Smith, C. R., Thomas, N. C., Martinson, M., Bergstrom, A., . . . Christensen, J. G. (2022). Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine. https://doi.org/10.1038/s41591-022-02007-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.